{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:07:14Z","timestamp":1787065634142,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T00:00:00Z","timestamp":1435017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11739-015-1270-0","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T06:10:56Z","timestamp":1434953456000},"page":"31-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience"],"prefix":"10.1007","volume":"11","author":[{"given":"Marta","family":"Fant\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Stefano","family":"Peragallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pietrosanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Di Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Picchianti Diamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"D\u2019Amelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,23]]},"reference":[{"issue":"1","key":"1270_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/kes189","volume":"52","author":"C Turesson","year":"2013","unstructured":"Turesson C, Matteson EL (2013) Malignancy as a comorbidity in rheumatic diseases. Rheumatology 52(1):5\u201314","journal-title":"Rheumatology"},{"issue":"1","key":"1270_CR2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.23185","volume":"58","author":"S Rohekar","year":"2008","unstructured":"Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD (2008) Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 58(1):82\u201387","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1270_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11926-010-0112-3","volume":"12","author":"ME Husni","year":"2010","unstructured":"Husni ME, Mease PJ (2010) Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 12(4):281\u2013287","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"1270_CR4","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","volume":"64","author":"ED Dommasch","year":"2011","unstructured":"Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64(6):1035\u20131050","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1270_CR5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","volume":"66","author":"RL Gross","year":"2014","unstructured":"Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman C, Mease PJ, Gottlieb AB, Kremer JM, Broder A (2014) A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 66(6):1472\u20131481","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1270_CR6","first-page":"71","volume":"32","author":"I Westhovens","year":"2014","unstructured":"Westhovens I, Lories RJ, Westhovens R, Verschueren P, de Vlam K (2014) Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clin Exp Rheumatol 32(1):71\u201376","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"1270_CR7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/ard.2002.004721","volume":"62","author":"N Feltelius","year":"2003","unstructured":"Feltelius N, Ekbom A, Blomqvist P (2003) Cancer incidence among patients with ankylosing spondylitis in Sweden 1965\u20131995: a population based cohort study. Ann Rheum Dis 62(12):1185\u20131188","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1270_CR8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899","journal-title":"Cell"},{"issue":"1","key":"1270_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1547691X.2013.798388","volume":"11","author":"RA Ponce","year":"2014","unstructured":"Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M (2014) Immunomodulation and lymphoma in humans. J Immunotoxicol 11(1):1\u201312","journal-title":"J Immunotoxicol"},{"issue":"1","key":"1270_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2011.12.005","volume":"22","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22(1):33\u201340","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1270_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361\u2013371","journal-title":"Nat Rev Cancer"},{"key":"1270_CR12","first-page":"241","volume":"2","author":"G Raval","year":"2010","unstructured":"Raval G, Mehta P (2010) TNF-\u03b1 inhibitors: are they carcinogenic? Drug Healthc Patient Saf 2:241\u2013247","journal-title":"Drug Healthc Patient Saf"},{"issue":"19","key":"1270_CR13","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275\u20132285","journal-title":"JAMA"},{"issue":"7","key":"1270_CR14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","volume":"68","author":"T Bongartz","year":"2009","unstructured":"Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68(7):1177\u20131183","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1270_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119\u2013130","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1270_CR16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2009","unstructured":"Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136\u20131145","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1270_CR17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE (2011) Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 63(6):1479\u20131485","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1270_CR18","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886\u20132895","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1270_CR19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","volume":"50","author":"W Amari","year":"2011","unstructured":"Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P (2011) Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology 50(8):1431\u20131439","journal-title":"Rheumatology"},{"issue":"9","key":"1270_CR20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308(9):898\u2013908","journal-title":"JAMA"},{"issue":"12","key":"1270_CR21","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","volume":"68","author":"TA Simon","year":"2009","unstructured":"Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, Suissa S (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68(12):1819\u20131826","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1270_CR22","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2012","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2012) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13(5):R141","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1270_CR23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","volume":"69","author":"X Mariette","year":"2010","unstructured":"Mariette X, Tubach F, Bagheri H, Bardet M, JBerthelot M, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P (2010) Lymphoma in patients treated with anti-TNF: results of the 3\u00a0year prospective French RATIO registry. Ann Rheum Dis 69(2):400\u2013408","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1270_CR24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstr\u00f6m C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54(3):692\u2013701","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1270_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","volume":"43","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD (2014) Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43(4):489\u2013497","journal-title":"Semin Arthritis Rheum"},{"key":"1270_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, JFries F, Cooper NS et al (1988) \u201cThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis\u201d. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1270_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55\u201378","journal-title":"Semin Arthritis Rheum"},{"key":"1270_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"1270_CR29","doi-asserted-by":"crossref","unstructured":"Smith AC, von Eschenbach R, Wender, BT, Levin Byers D, Rothenberger D, Brooks W, Creasman C, Cohen C, Runowicz D, Saslow V, Cokkinides H, Eyre (2001) For the ACS Colorectal Cancer Advisory Committee, and the ACS Endometrial Cancer Advisory Committee. \u201cAmerican Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001. Testing for early lung cancer detection\u201d. CA Cancer J Clin 51: 38\u201375","DOI":"10.3322\/canjclin.51.1.38"},{"issue":"3","key":"1270_CR30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","volume":"9","author":"FB Pallavicini","year":"2010","unstructured":"Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9(3):175\u2013180","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1270_CR31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/art.24506","volume":"61","author":"C Nannini","year":"2009","unstructured":"Nannini C, Cantini F, Niccoli L, Cassar\u00e0 E, Salvarani C, Olivieri I, Lally EV (2009) Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum 61(6):801\u2013812","journal-title":"Arthritis Rheum"},{"key":"1270_CR32","doi-asserted-by":"crossref","unstructured":"Jakob L, Metzler G, Chen KM, Garbe C (2011) Non-AIDS associated Kaposi\u2019s sarcoma: clinical features and treatment outcome. PLoS One 6(4):e18397","DOI":"10.1371\/journal.pone.0018397"},{"key":"1270_CR33","first-page":"326","volume":"32","author":"W Louthrenoo","year":"2003","unstructured":"Louthrenoo W, Kasitanon N, Mahanuphab P, Bhoopat L, Thongprasert S (2003) Kaposi\u2019s sarcoma in rheumatic disease. Semin Arthritis Rheum 32:326\u2013333","journal-title":"Semin Arthritis Rheum"},{"key":"1270_CR34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000277613","volume":"220","author":"D Nassar","year":"2010","unstructured":"Nassar D, Schartz NE, Bouch\u00e9 C, L\u00e9vy A, Kerob D, Agbalika F, Lafaurie M, Lebb\u00e9 C (2010) Kaposi\u2019s sarcoma after long-acting steroids: time until remission and drug washout. Dermatology 220:159\u2013163","journal-title":"Dermatology"},{"issue":"6","key":"1270_CR35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1529-8019.2012.01523.x","volume":"25","author":"V Amadu","year":"2012","unstructured":"Amadu V, Satta R, Montesu MA, Cottoni F (2012) Kaposi\u2019s sarcoma associated with treatment with adalimumab. Dermatol Ther 25(6):619\u2013620","journal-title":"Dermatol Ther"},{"key":"1270_CR36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jbspin.2009.10.006","volume":"76","author":"J Bret","year":"2009","unstructured":"Bret J, Hernandez J, Aquilina C, Zabraniecki L, Fournie B (2009) Kaposi\u2019s disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine 76:721\u2013722","journal-title":"Joint Bone Spine"},{"issue":"4","key":"1270_CR37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.110982","volume":"39","author":"LE Blay","year":"2012","unstructured":"Blay LE, Mouterde P, Barnetche T, Morel J, Combe B (2012) Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 39(4):712\u2013715","journal-title":"J Rheumatol"},{"issue":"3","key":"1270_CR38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, Gaujoux-Viala C, Nam JL, JSmolen S, Buch M, Gossec L, van der Heijde D, van der Heijde K, Landew\u00e9 R (2014) \u201cSafety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis\u201d. Ann Rheum Dis 73(3):529\u2013535","journal-title":"Ann Rheum Dis"},{"key":"1270_CR39","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1136\/bmj.f1939","volume":"346","author":"P Raaschou","year":"2013","unstructured":"Raaschou P, Simard JF, Holmqvist M, Askling J, ARTIS Study Group (2013) Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346:1939","journal-title":"BMJ"},{"key":"1270_CR40","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895\u20131904","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1270_CR41","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50(6):1740\u20131751","journal-title":"Arthritis Rheum"},{"key":"1270_CR42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.bor.0000126149.96627.82","volume":"16","author":"MFC Callan","year":"2004","unstructured":"Callan MFC (2004) Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 16:399\u2013405","journal-title":"Curr Opin Rheumatol"},{"key":"1270_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semarthrit.2005.01.008","volume":"34","author":"N Balandraud","year":"2005","unstructured":"Balandraud N, Roudier J, Roudier C, Pharm D (2005) What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis antagonism in rheumatoid arthritis? Semin Arthritis Rheum 34:31\u201333","journal-title":"Semin Arthritis Rheum"},{"key":"1270_CR44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","volume":"16","author":"E Baecklund","year":"2004","unstructured":"Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L (2004) Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 16:254\u2013261","journal-title":"Curr Opin Rheumatol"},{"key":"1270_CR45","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","volume":"99","author":"X Mariette","year":"2002","unstructured":"Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J (2002) The investigators of the Club Rheumatismes et Inflammation, \u201cLymphoma in rheumatoid arthritis patients treated with methotrexate: a 3\u00a0year prospective study in France\u201d. Blood 99:3909\u20133915","journal-title":"Blood"},{"key":"1270_CR46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajh.21003","volume":"82","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106\u20131109","journal-title":"Am J Hematol"},{"issue":"6","key":"1270_CR47","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","volume":"14","author":"E Salloum","year":"1996","unstructured":"Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, Schultz M, Murren J (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14(6):1943\u20131949","journal-title":"J Clin Oncol"},{"issue":"4","key":"1270_CR48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/keq417","volume":"50","author":"N Mo","year":"2011","unstructured":"Mo N, Muthu S, O\u2019Sullivan M (2011) Regression of lymphoma after withdrawal of infliximab alone in an infliximab\/methotrexate-treated RA patient. Rheumatology 50(4):808\u2013810","journal-title":"Rheumatology"},{"issue":"5","key":"1270_CR49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00296-007-0467-6","volume":"28","author":"SH Park","year":"2008","unstructured":"Park SH, Kim CG, Kim JY, Choe JY (2008) Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 28(5):475\u2013477","journal-title":"Rheumatol Int"},{"issue":"3","key":"1270_CR50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/s10165-008-0053-0","volume":"18","author":"A Komatsuda","year":"2008","unstructured":"Komatsuda A, Wakui H, Nimura T, Sawada K (2008) Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol 18(3):315\u2013318","journal-title":"Mod Rheumatol"},{"issue":"7","key":"1270_CR51","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard.2004.026252","volume":"64","author":"R Thonhofer","year":"2005","unstructured":"Thonhofer R, Gaugg M, Kriessmayr M, Neumann HJ, Erlacher L (2005) Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 64(7):1098\u20131099","journal-title":"Ann Rheum Dis"},{"key":"1270_CR52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/rheumatology\/kel396","volume":"46","author":"S Bernatsky","year":"2007","unstructured":"Bernatsky S, Lee JL, Rahme E (2007) Non-Hodgkin\u2019s lymphoma-meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology 46:690\u2013694","journal-title":"Rheumatology"},{"issue":"4","key":"1270_CR53","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2008.096925","volume":"69","author":"K Hellgren","year":"2010","unstructured":"Hellgren K, Iliadou A, Rosenquist R, Feltelius N, Backlin C, Enblad G, Askling J, Baecklund E (2010) Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study. Ann Rheum Dis 69(4):654\u2013659","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1270_CR54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/art.30653","volume":"64","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Mercer E, Kavanaugh A (2012) Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 64(1):21\u201332","journal-title":"Arthritis Rheum"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-015-1270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-015-1270-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-015-1270-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T17:28:53Z","timestamp":1559410133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-015-1270-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,23]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s11739-015-1270-0","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,23]]}}}